Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Personalized Models of Biological Barriers and Their Diseases: Recent Progress with Organs-On-Chips

Buck F., Bugter J., Yorukoglu G., Kazemzadeh Dastjerd M., Winkler TE.

Narrative Review on Neuroinflammation, published in Adv Biol (Weinh) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Adv Biol (Weinh) (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41671052
PMCID
PMC12893407
DOI
10.1002/adbi.202500536
Citations
3

Abstract (original English)

Barrier tissues-epithelial and endothelial interfaces that compartmentalize the human body-govern molecular exchange, immune surveillance, and organ homeostasis. Their dysfunction is central to disorders ranging from dermatitis to neurodegeneration. Conventional static cultures fail to capture the relevant microenvironment and typically rely on cell lines that overlook patient-specific genetics. Organs-on-chips (OoCs), by contrast, can recapitulate barrier-specific flow, biomechanics, chemical gradients, and a multicellular architecture. Additionally, incorporating primary or induced pluripotent stem cell (iPSC)-derived cells into OoCs can open new avenues for precision medicine. This review surveys the architectural diversity and physiological functions of human barrier systems and explores how OoC platforms-especially those using patient-derived cells-are advancing barrier disease modeling. It reveals similar core features but also unique barrier characteristics requiring specific adaptations, resulting in varied progress across systems, and continued refinement of iPSC differentiation protocols and OoC engineering is needed overall. Nevertheless, existing biological and technological advances already offer substantial, untapped opportunities to create physiologically relevant, patient-specific disease models and drug-testing platforms, bridging the gap between fundamental bi

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansModels, BiologicalLab-On-A-Chip DevicesInduced Pluripotent Stem CellsPrecision MedicineMicrophysiological Systems

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research